Eris Lifesciences (Mid Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Eris Lifesciences Limited |
|||
|
Price: ₹1,380.30 | ||
| 52 Week Low: ₹809.15 52 Week High: ₹1,593.90 |
|||
| Market Capital: 18,604.33 Crore (Midcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Eris Lifesciences Share Price Target For 2024
- 1.1.1: Eris Lifesciences Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Eris Lifesciences Share Price Target For 2025
- 1.2.1: Eris Lifesciences Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Eris Lifesciences Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Eris Lifesciences Brief Company Overview
- 4: Eris Lifesciences Financial Performance
- 4.0.1: Is Eris Lifesciences A Good Buy For Long Term?
To predict the Eris Lifesciences's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Eris Lifesciences Share Price Target For 2024
The line chart displays the monthly closing prices of Eris Lifesciences with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Eris Lifesciences shares in 2024, see the table below.
Eris Lifesciences Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 1440.15 (+4.33%) | Price Action: 06 Dec 2024 Low |
| 2024 Target 2 | 1422.75 (+3.07%) | Price Action: 18 Dec 2024 High |
| 2024 Target 1 | 1405.65 (+1.83%) | Price Action: 20 Dec 2024 High |
| Current Price | 1380.30 | Eris Lifesciences's share price as of 20 Dec 2024 |
| Stop Loss 1 | 1350.0 (-2.20%) | Price Action: 29 Oct 2024 High |
| Stop Loss 2 | 1326.65 (-3.89%) | Price Action: 12 Nov 2024 Low |
| Stop Loss 3 | 1312.0 (-4.95%) | Price Action: 13 Nov 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Eris Lifesciences is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 50-day moving average at ₹1380.77 serves as the nearest technical reference point.
Historical Returns: 3-month: +3.57% | 6-month: +34.87% | 1-year: +51.68%
Eris Lifesciences Share Price Target For 2025
The line chart displays the monthly closing prices of Eris Lifesciences with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Eris Lifesciences shares in 2025, see the table below.
Eris Lifesciences Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 1929.68 (+39.80%) | Price Action: Chart |
| 2025 Target 2 | 1893.7 (+37.19%) | Price Action: Chart |
| 2025 Target 1 | 1874.95 (+35.83%) | Fibonacci Extension Level 64.90% |
| Current Price | 1380.30 | Eris Lifesciences's share price as of 20 Dec 2024 |
| Stop Loss 1 | 1248.59 (-9.55%) | Price Action: Sep 2024 Low |
| Stop Loss 2 | 1227.82 (-11.05%) | Technical Indicator: MA150 |
| Stop Loss 3 | 1213.05 (-12.12%) | Price Action: Oct 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Eris Lifesciences is currently trading at 72.8% of its 52-week range (₹809.15 - ₹1593.9).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +51.68% | 3-year: +83.55% | 5-year: +201.84%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Eris Lifesciences Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹1,380.30 | ||
| 2024 | ₹1,497.32 | +8.48% | ₹1,519.78 |
| 2025 | ₹2,153.57 | +43.83% | ₹2,185.87 |
| 2026 | ₹2,717.82 | +26.20% | ₹2,758.59 |
| 2027 | ₹3,418.60 | +25.78% | ₹3,469.88 |
| 2028 | ₹4,133.57 | +20.91% | ₹4,195.57 |
| 2029 | ₹4,752.44 | +14.97% | ₹4,823.73 |
| 2030 | ₹5,416.61 | +13.98% | ₹5,497.86 |
| 2031 | ₹5,878.11 | +8.52% | ₹5,966.28 |
| 2032 | ₹6,643.73 | +13.02% | ₹6,743.39 |
| 2033 | ₹7,414.21 | +11.60% | ₹7,525.42 |
| 2034 | ₹8,007.56 | +8.00% | ₹8,127.67 |
| 2035 | ₹8,679.64 | +8.39% | ₹8,809.83 |
| 2036 | ₹9,038.40 | +4.13% | ₹9,173.98 |
| 2037 | ₹9,868.86 | +9.19% | ₹10,016.89 |
| 2038 | ₹10,694.85 | +8.37% | ₹10,855.27 |
| 2039 | ₹11,306.43 | +5.72% | ₹11,476.03 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Eris Lifesciences Brief Company Overview
Company Overview: Eris Lifesciences Limited Eris Lifesciences Limited, established in 2007, is an Indian pharmaceutical company based in Ahmedabad. It specializes in the manufacturing, marketing, and distribution of domestic branded formulations for chronic and...
sub-chronic therapies. Eris Lifesciences offers a comprehensive range of branded formulations catering to various therapeutic areas, including anti-diabetes, anti-infective, cardiovascular, dermatology, gastroenterology, neuropsychiatry, pain management, respiratory, and vitamins/minerals/nutrients. The company also provides patient care services such as blood pressure measurement, electrocardiogram measurement, glucose monitoring, sleep study, and ante-natal care solutions. Eris Lifesciences has a strong market presence across India, distributing its products through wholesale drug distributors, stockiest, and retail pharmacies. Reputation and Commitment: Eris Lifesciences has earned a reputation for quality and innovation in the pharmaceutical industry. The company is committed to providing affordable and accessible healthcare solutions to its customers.Eris Lifesciences Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 18,604.33 Crore | Market valuation of Eris Lifesciences's shares. |
| Revenue (TTM) | 2,485.28 Crore | Total revenue generated by Eris Lifesciences over the past twelve months. |
| Net Income (TTM) | +3,484,630,016.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +24.90% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +14.02% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+47.59% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
-25.80% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
86.07 | Company's total debt divided by total shareholder equity. |
| Total Debt | 2,734.82 Crore | Sum of Eris Lifesciences's current & long-term financial obligations. |
| Total Cash | 242.54 Crore | Total amount of liquid funds available to Eris Lifesciences. |
| Beta | 0.32 | Beta is less than 1 indicating that the Eris Lifesciences's price is less volatile than the market. |
Is Eris Lifesciences A Good Buy For Long Term?
Eris Lifesciences, a mid-cap stock with a market capitalization of ₹18,604.33 crore, shows strong recent performance: 59.03% return over the past 12 months and 135.69% over the past three years. However, Q2 2024-25 results reveal a concerning 25.8% year-on-year earnings decline despite a 47.59% revenue increase from the previous quarter. A 14.02% profit margin and significant debt (₹2,734.82 crore) against a relatively small cash balance (₹242.54 crore) raise concerns. While long-term growth potential exists, the current financial picture warrants caution. Therefore, it's currently an average buy, requiring further due diligence before a strong recommendation.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
